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work is the first stage for determining the design of pharmacology 
genetics research.
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Introduction: Oxycodone undergoes a relatively complicated metab-
olism producing 3 main metabolites: noroxycodone, oxymorphone, 
and noroxymorphone. Among these metabolites, oxymorphone is 
highly related to the pharmacodynamic effect of oxycodone. It is 14 
times more potent than the parent compound, and its affinity for the 
µ opioid receptor is 3 times higher than morphine. Development of a 
whole-body physiologically based pharmacokinetic (PK) model is an 
approach to predict in vivo metabolism of oxycodone and PK profile 
of each metabolite in different drug–drug interaction (DDI) scenarios.
Patients (or Materials) and Methods: The Simcyp simulator was used 
as a platform and database for simulation of oxycodone’s metabolism 
in virtual healthy populations. Prior in vitro and in vivo data were 
combined to build an oxycodone model which was used to predict 
the PK profile in healthy volunteers. The incorporated parameters 
were optimized by a top-down approach based on the clinical trial 
conducted by Samer et al, where PK profile of 0.2 mg/kg single dose 
oxycodone and its 3 metabolites were monitored in 10 healthy male 
volunteers (n = 10) previously genotyped for CYP2D6 in 4 scenar-
ios (oxycodone administered alone or coadministered with CYP3A 
inhibitor ketoconazole (400 mg) and/or CYP 2D6 inhibitor quinidine 
(100 mg)) (Samer C, Daali Y et al. 2010). The PK data obtained in 
3 interaction scenarios of the latter clinical trial were used to test 
the built model. Simulated trials permitted to evaluate the impact of 
CYP3A and CYP2D6 inhibitions on the concentration–time profiles 
of oxycodone and 3 main metabolites. The simulated studies designs 
were closely matched with the clinical trial and the virtual popula-
tions (1 trial of 10 volunteers, and 10 trials of 10 volunteers) were set 
with the same proportion of each CYP2D6 phenotype as the clinical 
trial (7 extensive, 1 poor and 2 ultrarapid metabolisers).
Results: Pharmacokinetic profiles of oxycodone and 2 predominant 
metabolites (oxymorphone and noroxycodone) were closely simu-
lated by the model.
Mean values (SD).
Oxycodone, noroxycodone, and oxymorphone PK profiles were 
also concordant with the clinical study according to CYP2D6 
phenotypic groups. Obtained DDI magnitudes were also in agree-
ment with the clinical data. Noroxymorphone PK profile was less 
accurately predicted by the model.
Conclusion: The Simyp developped model for oxycodone is valuable 
to predict the metabolism of oxycodone and main metabolites, and 
to simulate DDI involving CYP 3A and 2D6.
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Introduction: Oxcarbazepine (OXC) is a drug indicated for the treat-
ment of partial seizures or generalized tonic-clonic seizures in adults 
and children. It undergoes rapid presystemic reduction with forma-
tion of the active metabolite 10-hydroxycarbazepine (MHD), which 
has a chiral center at position 10, with the enantiomers (S)-(+)- and 
R-(-)-MHD with similar antiepileptic effects. OXC and MHD are 
substrates of P-glycoprotein (Pgp), whereas verapamil is an inhibitor 
of Pgp expressed in various tissues, including the brain. This study 
aims to evaluate the influence of verapamil on the pharmacokinetics 
of OXC and MHD enantiomers in healthy volunteers.
Patients (or Materials) and Methods: The study was conducted in 2 
phases and included 12 adult healthy volunteers. In the Phase I, they 
were treated with 300 mg/12 hours OXC during 5 days. On the fifth 
day, after the last dose, serial blood samples were collected up to 12 
hours. In the Phase II, the same healthy volunteers were treated with 
OXC (300 mg/12 hours during 5 days) associated with verapamil (80 
mg/8 hours during 5 days). On the fifth day, after the last OXC dose, 
serial blood samples were collected up to 12 hours. Plasma concentra-
tions of OXC and MHD enantiomers were evaluated by LC-MS/MS 
coupled with a chiral phase Chiralcel® OD-H column. Pharmacokinetic 
analysis was performed using the software WinNonlin and statistical 
tests were conducted with the significance level set at P < 0.05.
Results: The following pharmacokinetic parameters for OXC were 
obtained in Phase I (median): maximum plasma concentration (Cmax) 
of 1.35 mg/mL in 1.0 hour, area under the plasma concentration 
versus time curve (AUC0–12) of 3.98 μ g·h/mL and half-life of 2.45 
hours. The kinetic disposition of MHD was enantioselective, with 
observation of a higher proportion for the enantiomer S-(+)-MHD 
compared with R-(-)-MHD (AUC0-12S-(+) / R-(-) of 4.10). Verapamil 
treatment (Phase II) decreased the mean residence time (3.83 vs 4.71 
hours) and the apparent volume of distribution (Vdárea /f’)(2.86 vs 
3.78 L/kg) of OXC. Concerning MHD enantiomers, the verapamil 
treatment increased Cmax, AUC and Css for both enantiomers.
Conclusion: Verapamil treatment reduced OXC Vdárea/f’ and 
increased AUC of both MHD enantiomers probably due to the Pgp 
inhibition.
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AUC24h (ng·min/mL) Cmax (ng/mL)
Observed Simulated Simulated Observed Simulated Simulated
n = 10 n = 10 n = 100 n = 10 n = 10 n = 100
Oxycodone 12,086 
(3184)
12,305 
(8002)
12,953 
(6088)
35.9 
(11.3)
32.2 
(14.8)
35.3 
(13.6)
Noroxycodone 7753 
(2127)
7101 
(4442)
7502 
(4875)
15.5 
(4.3)
14.3 
(6.7)
15.3 
(9.7)
Oxymorphone 232 
(142)
179 (145) 244 (267) 0.7 (0.4) 0.7 (0.7) 0.8 (0.7)
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Introduction: Selexipag is a new prostacyclin receptor agonist, 
which is being investigated in Phase III studies for the treatment of 
pulmonary arterial hypertension (PAH). Renal function impairment 
can alter the disposition of a large number of drugs and since PAH 
patients may have impaired renal function, the aim of this study was 
to assess how severe renal function impairment (SRFI) may affect the 
pharmacokinetics (PK), safety, and tolerability of selexipag and its 
active metabolite (ACT-333679).
Patients (or Materials) and Methods: Sixteen subjects were enrolled 
in this 2-group Phase I study. Groups A and B were composed of 8 
subjects with SRFI and 8 healthy subjects, respectively. Subjects in 
Group B were matching with those in Group A, based on age, sex, 
race, and body mass index. Subjects received a single oral dose of 
400 µg selexipag and were monitored for 144 h (Group A) or 72 h 
(Group B). PK samples were analyzed by liquid chromatography 
coupled to tandem mass spectrometry. PK parameters of selexipag 
and ACT-333679 were explored using ratios of geometric means 
and their 90% CIs.
Results: PK results (geometric mean (95% CI)) are presented in the 
table below:
No relevant differences in plasma protein binding of selexipag 
and ACT-333679 were observed between both groups. Five sub-
jects reported 17 adverse events (AEs): 8 in Group A, 9 in Group B. 
Headache was the most frequently reported AE in both groups (4 
in each group). No clinically relevant changes in mean vital signs, 
electrocardiograms, clinical laboratory variables, including estimated 
glomerular filtration rate and urinalysis, were observed. No deaths 
or serious adverse events were reported.
Conclusion: Selexipag 400 µg was generally well tolerated in all sub-
jects. Compared with healthy subjects, a 1.7-fold increase in Cmax 
and AUC to selexipag was observed in subjects with SRFI. Similar 
results were obtained for ACT-333679, i.e., a 1.4-fold increase in 
Cmax and an approximately 1.7-fold increase in AUC in subjects 
with SRFI compared with healthy subjects.
Disclosure of Interest: None declared.
PP193—SiMulTANeouS lC-MS/MS 
QuANTifiCATioN of P-glyCoProTeiN ANd 
CyToChroMe P450 ProBe SuBSTrATeS ANd 
Their MeTABoliTeS iN dried Blood SPoTS
M. Bosilkovska1*; J. Deglon2; C. Samer1,3; B. Walder4; P. Dayer1;  
J. Desmeules1,3; C. Staub2,3; and Y. Daali1,3
1Clinical Pharmacology and Toxicology, Geneva University 
Hospitals; 2Unit of Toxicology, University Center of Legal 
Medicine; 3Swiss Centre for Applied Human Toxicology; 
and 4Anesthesiology, Geneva University Hospitals, Geneva, 
Switzerland
Introduction: Modifications in cytochrome P450 (CYP) and/or 
transporter activities (such as P-glycoprotein [P-gp]) can result in 
important pharmacokinetic variability and are the underlying mecha-
nism of many drug–drug interactions. CYP and P-gp activity can be 
assessed by the in vivo administration of a cocktail of probe drugs 
each of which is metabolized by 1 specific cytochrome or transported 
by P-gp.
Patients (or Materials) and Methods: In this study, a single 
HPLC-MS/MS method has been developed for the simultaneous 
quantification of P-gp (fexofenadine) and CYP probe substrates (caf-
feine for CYP1A2, bupropion for CYP2B6, flurbiprofen for CYP2C9, 
omeprazole for CYP2C19, dextromethorphan for CYP2D6 and 
midazolam for CYP3A), and their metabolites in dried blood spots 
(DBS). Substances were extracted from DBS (10 µL) using methanol. 
DBS analysis was performed using a LC-MS/MS system consisting 
of a 5500QTrap® triple quadrupole linear ion trap (QqQLIT) mass 
spectrometer equipped with a TurboIon SprayTM interface and an 
Ultimate 3000 RS instrument as LC system.
Results: The method was validated according to international crite-
ria. The intermediate precision was < 10% and the accuracy was in 
the interval (92.2%–111.1%) for all substances and all concentra-
tions tested. A linear response was observed for the following con-
centration ranges: 1 to 200 ng/mL for bupropion, hydroxybupropion, 
and fexofenadine; 0.1 to 100 ng/mL for midazolam; 0.2 to 200 ng/
mL for omeprazole, hydroxyomeprazole, hydroxymidazolam, and 
dextromethorphan; 0.5 to 500 ng/mL for dextrorphan; 50 to 10,000 
ng/mL for caffeine and paraxanthine; 50 to 2500 ng/mL for flurbi-
profen and 5 to 1000 ng/mL for hydroxyflurbiprofen. All substances 
were stable in DBS stored at room temperature for at least 15 days. 
The method has been successfully applied to a pharmacokinetic study 
where healthy male volunteers have received a low-dose cocktail of 
the here described P-gp and CYP probe substances. Metabolic ratios 
were determined for all CYP probe drugs and a good correlation was 
observed when drug concentrations in capillary DBS samples were 
compared with venous plasma samples.
Conclusion: DBS is a suitable sampling method for cytochromes and 
P-glycoprotein phenotyping.
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Introduction: Selexipag is a new prostacyclin receptor agonist, which 
is being investigated in Phase III studies for the treatment of pulmo-
nary arterial hypertension (PAH). Selexipag is eliminated for > 90% 
by the liver and because PAH patients may suffer from liver impair-
ment, the aim of this study was to assess how different degrees of 
liver impairment may affect the pharmacokinetics (PK), safety, and 
tolerability of selexipag and its active metabolite (ACT-333679).
Patients (or Materials) and Methods: Twenty-six subjects were 
enrolled in this 4-group Phase 1 study. Group A, B, C, and D were 
composed of 8 subjects with mild liver impairment, 8 subjects with 
moderate liver impairment, 2 subjects with severe liver impairment, 
and 8 healthy subjects, respectively. Subjects of Group D were match-
ing with those of Group B, based on age, sex, body weight, and 
height. Subjects received a single oral dose of selexipag (400 µg for 
Parameter Group A Group B
Selexipag ACT-333679 Selexipag ACT-333679
Cmax1 [ng/mL] 5.4 (3.9–7.4) 7.3 (6.1–8.7) 3.1 (2.1–4.5) 5.1 (3.2–8.2)
Tmax2 [h] 2.0 (1.0–5.0) 4.0 (1.5–6.0) 1.5 (0.5–6.0) 4.5 (2.0–8.0)
t1/23 [h] 1.0 (0.7–1.5) 13.4 (7.1–25.4) 1.4 (0.8–2.2) 8.3 (7.0–9.9)
AUC0–∞4 
[ng*h/mL]
17.1 (13.4–
21.6)
70.6 (29.3–
170.3)
9.9 (7.4–13.2) 43.7 (14.6–
131.1)
1peak concentration; 2time to reach Cmax; median (range); 3terminal half-life; 4exposure 
from 0 to ∞.
